EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 9, 2012--
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc.
(Nasdaq: SRDX) and a market leader for in
vitro diagnostic assay components, is pleased to announce it will
launch BioFX®
TMB Extended Range HRP Microwell Substrate (TMBX) at the
American Association for Clinical Chemistry show in Los Angeles, CA from
July 17-19, 2012.
Use of BioFX TMBX
in a quantitative assay (i) can increase the assay's upper limit of
quantitation and (ii) maintain the detection limits and analytical
sensitivity achieved with other SurModics TMB substrates. TMBX also
improves the reproducibility of the assay through lower backgrounds and
better control of assay timing. TMBX is our slowest kinetic option of
TMB substrates for extended dynamic range and improved reproducibility
within.
“This newest addition to SurModics’ line of TMB substrate products
further demonstrates the flexibility of our capabilities to support the in
vitro diagnostics industry and its extended dynamic range needs,”
said Gary Maharaj, president and chief executive officer of SurModics.
“SurModics is committed to using its diagnostic history and expertise to
develop and improve products, including custom formulation options to
better serve our customers.”
To learn more about SurModics' in vitro diagnostic products,
please visit our website (www.surmodics.com),
or contact customer service at 952-500-7200 or orders@surmodics.com.
SurModics IVD now offers easy online ordering of over 900 IVD products
available at http://shop.surmodics.com.
SurModics is a registered trademark of SurModics, Inc.
About SurModics, Inc.
SurModics' mission is to exceed our
customers' expectations and enhance the well-being of patients by
providing the world's foremost, innovative surface modification
technologies and in vitro diagnostic chemical components. The
Company partners with the world's leading and emerging medical device,
diagnostic and life science companies to develop and commercialize
innovative products designed to improve patient diagnosis and treatment.
Core offerings include (i) surface modification coating technologies
that impart lubricity, prohealing, and biocompatibility capabilities,
and (ii) components for in vitro diagnostic tests and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For
more information about the Company, visit http://www.surmodics.com.
The content of SurModics' website is not part of this release or part of
any filings the Company makes with the SEC.
Source: SurModics, Inc.
SurModics, Inc.
Tim Arens, vice president of finance and interim
chief financial officer
952-500-7000
